Neil A Hanchard1, Joann M Moulds2, John W Belmont1, Alice Chen3. 1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA ; ARS/USDA/Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. 2. Scientific Support Services, LifeShare Blood Centers, Shreveport, LA, USA. 3. Department of Pathology, Texas Heart Institute, Baylor St. Luke's Medical Center, Houston, TX, USA.
Abstract
BACKGROUND: A selective susceptibility of certain individuals to form multiple alloantibodies in response to red cell transfusion is well-recognized in clinical practice, and is a particular problem in persons with sickle cell disease (SCD). The reason for this differential susceptibility is unclear, but inter-individual genetic differences are likely to contribute. METHODS: We conducted a pilot case-control genome-wide association study using 1,000,000 SNPs in 94 alloimmune responders (cases) and non-responders (controls) with SCD in order to identify loci of large effect size associated with alloimmunization. RESULTS: No loci showed evidence of association at a genome-wide significance cut-off (p < 0.5 × 10(-8)). SNPs in the ARAP1/STARD10 region showed suggestive association (p < 1 × 10(-6)), but no association was observed at previously implicated loci TRIM21 or HLA. In analyses of the number of accumulated antibodies, a modest association was found with SNPs in the Toll-like receptor gene TLR10 (p < 1 × 10(-4)). CONCLUSIONS: Alloimmunization in persons with SCD is unlikely to be mediated by loci of very large effect size; however, larger and more comprehensive studies are required to fully evaluate loci with more moderate effects. This study provides a working approach to such future studies in SCD.
BACKGROUND: A selective susceptibility of certain individuals to form multiple alloantibodies in response to red cell transfusion is well-recognized in clinical practice, and is a particular problem in persons with sickle cell disease (SCD). The reason for this differential susceptibility is unclear, but inter-individual genetic differences are likely to contribute. METHODS: We conducted a pilot case-control genome-wide association study using 1,000,000 SNPs in 94 alloimmune responders (cases) and non-responders (controls) with SCD in order to identify loci of large effect size associated with alloimmunization. RESULTS: No loci showed evidence of association at a genome-wide significance cut-off (p < 0.5 × 10(-8)). SNPs in the ARAP1/STARD10 region showed suggestive association (p < 1 × 10(-6)), but no association was observed at previously implicated loci TRIM21 or HLA. In analyses of the number of accumulated antibodies, a modest association was found with SNPs in the Toll-like receptor gene TLR10 (p < 1 × 10(-4)). CONCLUSIONS: Alloimmunization in persons with SCD is unlikely to be mediated by loci of very large effect size; however, larger and more comprehensive studies are required to fully evaluate loci with more moderate effects. This study provides a working approach to such future studies in SCD.
Entities:
Keywords:
African American; GWAS; Genome-wide association studies; Genomics; Responders
Authors: Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses Journal: Lancet Date: 2002-03-30 Impact factor: 79.321
Authors: Aditi Hazra; Peter Kraft; Ross Lazarus; Constance Chen; Stephen J Chanock; Paul Jacques; Jacob Selhub; David J Hunter Journal: Hum Mol Genet Date: 2009-09-10 Impact factor: 6.150
Authors: Stella T Chou; Tannoa Jackson; Sunitha Vege; Kim Smith-Whitley; David F Friedman; Connie M Westhoff Journal: Blood Date: 2013-05-30 Impact factor: 22.113
Authors: Zohreh Tatari-Calderone; Ryad Tamouza; Gama P Le Bouder; Ramita Dewan; Naomi L C Luban; Jacqueline Lasserre; Jacqueline Maury; François Lionnet; Rajagopal Krishnamoorthy; Robert Girot; Stanislav Vukmanovic Journal: Clin Dev Immunol Date: 2013-05-22
Authors: Muminatou Jallow; Yik Ying Teo; Kerrin S Small; Kirk A Rockett; Panos Deloukas; Taane G Clark; Katja Kivinen; Kalifa A Bojang; David J Conway; Margaret Pinder; Giorgio Sirugo; Fatou Sisay-Joof; Stanley Usen; Sarah Auburn; Suzannah J Bumpstead; Susana Campino; Alison Coffey; Andrew Dunham; Andrew E Fry; Angela Green; Rhian Gwilliam; Sarah E Hunt; Michael Inouye; Anna E Jeffreys; Alieu Mendy; Aarno Palotie; Simon Potter; Jiannis Ragoussis; Jane Rogers; Kate Rowlands; Elilan Somaskantharajah; Pamela Whittaker; Claire Widden; Peter Donnelly; Bryan Howie; Jonathan Marchini; Andrew Morris; Miguel SanJoaquin; Eric Akum Achidi; Tsiri Agbenyega; Angela Allen; Olukemi Amodu; Patrick Corran; Abdoulaye Djimde; Amagana Dolo; Ogobara K Doumbo; Chris Drakeley; Sarah Dunstan; Jennifer Evans; Jeremy Farrar; Deepika Fernando; Tran Tinh Hien; Rolf D Horstmann; Muntaser Ibrahim; Nadira Karunaweera; Gilbert Kokwaro; Kwadwo A Koram; Martha Lemnge; Julie Makani; Kevin Marsh; Pascal Michon; David Modiano; Malcolm E Molyneux; Ivo Mueller; Michael Parker; Norbert Peshu; Christopher V Plowe; Odile Puijalon; John Reeder; Hugh Reyburn; Eleanor M Riley; Anavaj Sakuntabhai; Pratap Singhasivanon; Sodiomon Sirima; Adama Tall; Terrie E Taylor; Mahamadou Thera; Marita Troye-Blomberg; Thomas N Williams; Michael Wilson; Dominic P Kwiatkowski Journal: Nat Genet Date: 2009-05-24 Impact factor: 38.330
Authors: Lesedi M Williams; Zhihua Qi; Ken Batai; Stanley Hooker; Nancy J Hall; Roberto F Machado; Alice Chen; Sally Campbell-Lee; Yongtao Guan; Rick Kittles; Neil A Hanchard Journal: Blood Adv Date: 2018-12-26
Authors: Savannah Mwesigwa; Joann M Moulds; Alice Chen; Jonathan Flanagan; Vivien A Sheehan; Alex George; Neil A Hanchard Journal: Transfusion Date: 2017-12-06 Impact factor: 3.157